Table 1. Baseline characteristics and follow-up data.
| Characteristics | All (n = 527) | Cirrhosis (+) (n = 218) | Cirrhosis (-) (n = 309) | P value |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age (years) | 48.8± 9.9 | 51.5 ± 8.7 | 46.8 ± 10.2 | < 0.001 |
| Male (n, %) | 311 (59.0) | 141 (64.7) | 170 (55.0) | 0.03 |
| AST (U/L) | 34 (25–54) | 43 (30–63) | 29 (23–47) | < 0.001 |
| ALT (U/L) | 37 (24–66) | 40 (27–69) | 34 (22–63) | 0.01 |
| Albumin (mg/dl) | 4.4 (4.1–4.6) | 4.3 (3.9–4.5) | 4.5 (4.3–4.7) | < 0.001 |
| Bilirubin (mg/dl) | 0.8 (0.6–1.1) | 0.9 (0.7–1.2) | 0.8 (0.6–1.0) | < 0.001 |
| PT (INR) | 1.0 (1.0–1.1) | 1.1 (1.0–1.2) | 1.0 (1.0–1.1) | < 0.001 |
| Platelet (x 103/L) | 168 (128–210) | 118 (94–138) | 199 (173–229) | < 0.001 |
| HBV DNA (log10 IU/ml) | 4.9 ± 1.2 | 5.1 ± 1.3 | 4.7 ± 1.1 | <0.001 |
| qHBsAg (log10 IU/ml) | 3.3 ± 0.6 | 3.2 ± 0.6 | 3.4 ± 0.6 | < 0.001 |
| Follow-up data | ||||
| AVT during follow-up (n, %) | 311 (59.0) | 175 (80.3) | 136 (44.0) | < 0.001 |
| Disease progression (n, %) | 46 (8.7) | 39 (17.9) | 7 (2.3) | < 0.001 |
| HCC | 40 (7.6) | 33 (15.1) | 7 (2.3) | < 0.001 |
| Cirrhotic complication | 6 (1.1) | 6 (2.8) | 0 (0) | 0.01 |
| Inactive carrier (n, %) | 31 (5.9) | 31 (10.0) |
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalization ratio; HBV, hepatitis B virus; qHBsAg, quantitative hepatitis B surface antigen; AVT, antiviral therapy; HCC, hepatocellular carcinoma. Values are expressed as mean ± standard deviation, median (quartile), or number (%).